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questionnaire regarding their medical care and self management. Medications (within 
the last 7 days), physical examination and laboratory tests were documented. DDMP 
participation was validated by the primary physician. Only DM2s with statutory 
health insurance and validated DDMP enrolment were included in the analysis (n  
166). Regression analyses adjusting for confounders (age, sex, education, diabetes 
duration and previous diabetes complications) were conducted. RESULTS: DDMP 
enrolees (n  89) reported medical examination of eyes and feet and medical advice 
regarding diet and physical activity more frequently (p  0.005), received antidiabetic 
and antihypertensive medications more often (p  0.05) and attended diabetes educa-
tion more frequently (p  0.005). DDMP enrolees measured their blood pressure more 
frequently (p  0.05). The groups did not differ regarding Hemoglobin A1c (HbA1c), 
but of 54 DM2s with values over 7%, only 3.6% of DDMP enrolees were receiving 
no antihyperglycemic medication whereas this was true for 38.5% of those not in 
DDMP. This difference remained signiﬁcant (p  0.0129) after adjustment for diabetes 
duration. CONCLUSIONS: According to our study, health care quality in DDMPs is 
improved. However, patient self-management of all diabetics must be improved.
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OBJECTIVES: Diabetes extracts a considerable economic toll on the US health care 
system. An analysis conducted in 2007, indicated that the economic burden of diabetes 
was $174 billion, with direct medical expenditures accounting for $116 billion. Origi-
nally published in 2006 and updated yearly, the American Diabetes Association 
(ADA)/European Association for the Study of Diabetes (EASD) Consensus Algorithm 
for the Initiation and Adjustment of Therapy, stands to guide health care practitioners 
in determining the most appropriate lifestyle and pharmacotherapeutic interventions 
for patients with Type 2 diabetes. We conducted an analysis to compare medication 
regimens from claims adjudicated by patients with Type 2 diabetes to treatment regi-
mens outlined in the ADA/EASD guidelines. METHODS: This retrospective claims 
analysis utilized data from the 2007 MarketScan® Commercial Claims and Encoun-
ters and the Medicare Supplemental and Coordination of Beneﬁts databases from 
Thomson Reuters. Medication regimens were evaluated for patients with Type-2 dia-
betes and at least one prescription claim for the fourth quarter of 2007. In order to 
be considered as part of a treatment regimen all medications must have had an over-
lapping 45 day period of utilization in the quarter. All identiﬁed medication regimens 
were compared to 2008 ADA/EASD consensus guidelines RESULTS: A total of 
191,535 patients were included in the analysis. In rank order, the top ﬁve treatment 
regimens by utilization frequency were as follows: biguanide monotherapy (27.9%), 
sulfonylurea monotherapy (14.53%), sulfonylureabiguanide combination therapy 
(12.01%), thiazolidinedione monotherapy (9.21%), thiazolidinedionebiguanide 
combination therapy (6.97%). CONCLUSIONS: As expected, following ADA/EASD 
guidelines, monotherapy with biguanide and a regimen of biguanidesulfoylurea were 
among the most frequently utilized regimens. The high degree of sulfonylurea mono-
therapy utilization may suggest that many patients may not tolerate monotherapy with 
biguanide. In all cases treatment must be individualized requiring the use of other 
agents to control blood glucose levels.
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OBJECTIVES: Suboptimal compliance and failure to persist with antidiabetes thera-
pies are of potential economic signiﬁcance. The present research aims to review the 
recent literature regarding the impact of poor compliance and persistence with antidi-
abetes medications on the cost of health care or its components for patients with type 
2 diabetes mellitus (T2DM). METHODS: Systematic literature search was conducted 
in pubmed for relevant articles published in the period between January 1, 2000 and 
April 30, 2009. Studies describing economic consequence of compliance and/or per-
sistence with pharmaceutical antidiabetes treatment were identiﬁed. RESULTS: Of 
449 articles corresponding to the primary search algorithm, 12 studies (all conducted 
in USA) fulﬁlled inclusion criteria regarding the economic impact of compliance and/or 
persistence with treatment on the overall cost of T2DM care or its components. 
Compliance was assessed via medication possession ratio (MPR) in 10 studies, and 
ranged from 0.52 to 0.93 depending on regimen. Persistence was assessed in one study. 
Mean total annual costs per patient having T2DM varied between the studies, ranging 
from $4,570 to $17,338. In 7 studies medication compliance was inversely associated 
with total health care costs, while in four other studies inverse associations between 
medication compliance and hospitalisation costs were reported. In one study increased 
adherence did not change overall health care costs. CONCLUSIONS: Improved com-
pliance can lead to reductions of the total health care costs in T2DM, mainly through 
decrease in hospitalisations. Studies assessing economic impact of persistence with 
pharmacotherapy in T2DM are limited, and studies investigating cost consequences 
of compliance are predominantly using MPR as a measure of compliance. Further 
research is needed in countries other than USA to assess impact of compliance and 
persistence to pharmacotherapy on T2DM costs in country-speciﬁc settings. Research-
ers should follow deﬁnitions of compliance and persistence proposed by the ISPOR 
Medication Compliance and Persistence Special Interest Group.
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OBJECTIVES: Meta-Analyses of oral hypoglycemic agents (OHA) revealed that Rosi-
glitazone (Rosi) increased the risk of Myocardial Infarction (MI) and Heart Failure 
(HF), and Pioglitazone (Pio) increased the risk of HF and decreased the risk of MI. 
The objective of this research is to compare OHA utilization patterns, before and after 
these publications. METHODS: CareFirst BlueCross BlueShield’s claims were ana-
lyzed for patients continuously enrolled from January 2005 through December 2007 
who started on mono-Rosi or mono-Pio. The “pre-publication” period (November 1, 
2006—March 31, 2007) was compared to the “post-publication” period (July 1, 
2007—December 1, 2007) using a difference-in-difference approach. Multinomial 
logistic regression (MLR) explored discontinuation; continuation with monotherapy 
or adding another drug; and switching after adjusting for gender, age, type of insur-
ance, history of MI or HF and risk factors for MI and HF. RESULTS: The number 
of monotherapy Rosi users decreased from the pre (N  368, 5.94%) to post (N  
170, 2.87%) period, while monotherapy Pio use was stable across the two periods. 
The proportion who switched from Rosi to non-Rosi drugs changed from 2.17% in 
pre-period to 5.88% in post period. Adjusted relative risk was 2.66 (95 % CI 1.0569, 
6.7689). Pio to non-pio drugs switching was 1.48% in pre-period and 1.16% in post-
period (relative risk not signiﬁcant). Therefore, the impact of the new studies on Rosi 
users to switch to non-Rosi drug, relative to Pio users before and after the publication 
was 3.6189 (90%CI 1.051, 12.457). CONCLUSIONS: Consistent with prior research, 
the utilization of Rosi declined by more than half in the post-period. Additionally, 
Rosi users were three times more likely to switch to a non-Rosi drug in the post period, 
relative to Pio users. Therefore, our results show that the publications about safety 
risks had differential impact between the two drugs within therapeutic class.
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OBJECTIVES: Following a commitment to an intensive glucose-lowering regimen that 
includes mealtime insulin is eventually required by patients taking basal insulin to 
maintain good glycemic control. The objective of this study was to characterize and 
examine factors associated with persistence to mealtime insulin. METHODS: Patients 
with diagnosed type-2 diabetes, with at least 2 prescriptions for mealtime insulin 
(index medication) between July 2001 and Sept 2006, were identiﬁed from a US 
managed care claims database. Patients were required to have 6 months pre- and 15 
months post-index continuous eligibility and at least 2 basal insulin prescriptions in 
pre-index period. Persistence measure #1 was deﬁned by the absence of prescription 
gap of greater than 90 days, with non-persistence effective the date of the last prescrip-
tion prior to the 90 day gap. Persistence measure #2 required one prescription per 
quarter to be persistent at 12 months; persistence at 3 and 6 months were deﬁned 
similarly. Logistic regression models were used to examine predictors of persistence 
to mealtime insulin at 12 months. RESULTS: Patients adding mealtime insulin to their 
basal regimen (n  4,752; 51% male, mean age  60.3 years) mostly used insulin 
analogs (60%) and vial/syringe (87%). The median number of mealtime insulin pre-
scription claims ﬁlled per patient was 2, 3 and 4 at 3, 6 and 12 months respectively, 
with the median time between reﬁlls being 75.5 days. Persistence to mealtime insulin 
was 40.7%, 30.2% and 19.1% using measure #1 and 74.3%, 55.3% and 42.2% using 
measure # 2 at 3, 6 and 12 months, respectively. Patients initiating with human insulin 
were less likely to be persistent across measures of persistence (OR  0.80, p  0.01). 
Additional predictors of persistence at 12 months included age, copayment, mental 
health comorbidity and polypharmacy. CONCLUSIONS: Persistence to insulin 
therapy is poorer than one would anticipate and is signiﬁcantly lower for human 
insulin compared to analogs.
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OBJECTIVES: Using the Dutch PHARMO database, the aim was to 1) determine the 
percentage of type 2 diabetes (T2D) patients starting on long-acting insulin analogues 
versus NPH; 2) compare previous insulin experience in patients; and 3) establish the 
number of patients changing treatment within one year. METHODS: The PHARMO 
database includes community pharmacy drug dispensing and hospitalisation records 
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from approximately 2.5 million patients. Data was extracted for insulin naïve and 
prior insulin T2D patients initiated on basal insulin as monotherapy or as part of a 
basal-bolus regimen in 2004–2006. RESULTS: The study included 7209 new basal 
insulin users, of which 4792 (67%) were insulin naive. Overall, 4728 (66%) used 
analogues, with similar proportions using monotherapy (67%) and basal-bolus 
therapy (65%). The proportion of analogue users was greater among prior insulin 
users: 541 of 619 (87%) for monotherapy and 1331 of 1798 (74%) for basal-bolus 
therapy compared with 2258 of 3702 (61%) and 598 of 1090 (55%) among naïve 
users. Monotherapy for naïve patients was initiated mainly by the GP (NPH 70%, 
analogue 59%), for prior users mainly by the internist (NPH 49%, analogue 59%)%), 
same as for basal-bolus users (NPH 67–68%, analogue 75–80%). With NPH, 22% 
discontinued their prescription (average of 220 days) and with basal analogues 17% 
(average of 230 days). Furthermore, 6% of patients on NPH and 11% with basal 
analogues added-on to their prescription (after an average of 119 days and 126 days, 
respectively). Only 17% of patients switched treatment with basal analogues com-
pared with NPH (average of 190 days) versus 32% (average of 158 days), respectively. 
CONCLUSIONS: When new insulin treatment is initiated, analogues are more often 
prescribed than NPH, more frequently prescribed by Dutch internists and not discon-
tinued or switched as frequently as NPH, indicating that basal insulin analogues give 
a more sustained and satisfactory result.
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OBJECTIVES: Many aspects of the scientiﬁc, economic and political discussions on 
the beneﬁt of new medicines, for which modern insulins are a pivotal example, inﬂu-
ence recent decisions about drug reimbursement. This study was undertaken to 
compare the reimbursement status of long acting insulin analogues (LAIA) in several 
industrialized countries around the globe, where different criteria for public funding 
of pharmaceuticals have been used, but all include estimates of clinical effectiveness 
and/or cost effectiveness. METHODS: The study was performed based on a combina-
tion of desk research, direct contact with national diabetes stakeholders and expert 
review, using a pre-deﬁned questionnaire. In the ﬁrst phase, information was gathered 
from each country on diabetes prevalence, cost, relevant policies and guidelines through 
a range of sources including government and patient association websites, published 
scientiﬁc literature, media reports. In the second phase additional information about 
reimbursement status of LAIA was sought from recommendations obtained from the 
websites of HTA or similar agencies, or interviews carried out with national stakehold-
ers representing health ministries, patient organisations or medical community. 
RESULTS: Fifteen countries have been included in the study (Australia, New Zealand, 
Canada, UK, The Netherlands, France, Germany, Austria, Sweden, Norway, Latvia. 
Lithuania, Estonia, Hungary, Bulgaria). Only in France LAIA are reimbursed in 65%, 
in all remained countries—in 100%. But in most countries there are several restrictions 
on access to LAIA, namely criteria for this type of treatment have been developed to 
respond the clinical and economic evidence (use in selected patients, application only 
from a relevant specialist, regular reassessments of metabolic control, listing after the 
company agreed to a price reduction). CONCLUSIONS: The story of LAIA is impor-
tant not only because of the way the evidence has been interpreted, but because the 
voice of consultative bodies resulted in action by the health care purchasers.
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OBJECTIVES: The aim of this study was to collect comparable and reliable data about 
consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 
1999–2008. METHODS: Data of wholesalers (following ATC/DDD), who are legally 
obliged provide this information to the Slovak Institute for Drug Control, was used 
for the analysis. The results were expressed in the numbers of the packages, ﬁnance 
units (a) and deﬁned daily doses per 1000 inhabitants per day (DID). RESULTS: The 
collected data shows a signiﬁcant increases in the antidiabetic’s consumption from 
1999 to 2008 in term of DID (in 1999 (33.34) and in 2008 (48.63)). A moderate 
increase in A10AB group (Insulins and analogues, fast-acting) in 1999 (3.03), in 2003 
(3.47) and in 2008 (5.25), a signiﬁcant decrease in A10AC group (Insulins and ana-
logues, intermediate-acting) in 1999 (4.79), in 2003 (3.94) and in 2008 (2.20), a 
moderate increase in A10AD (Insulins and analogues, intermediate-acting combin.) in 
1999 (2.47), in 2003 (2.71) and in 2008 (4.05), a noticeable increase in A10AE 
(Insulins and analogues, long-acting) in 1999 (0.05), in 2003 (0.02) and in 2008 
(1.99), a dramatic increase in A10BA (Biguanides) in 1999 (4.82), in 2003 (7.66) and 
in 2008 (13.51), a relatively stable consumption in A10BB (Sulfonamides) in 1999 
(17.57), in 2003 (15.87) and in 2008 (19.29) and a moderate increase in A10BD 
(Biguanides and sulfonamides in combination) in 1999 (0.52), in 2003 (0.95) and in 
2008 (1.68) in term of DID can be seen from this analysis. Financial expenditures for 
antidiabetics were in 1999 (a19,271,000) and in 2008 (a38,952,000). CONCLU-
SIONS: Inseparable components of the Slovak drug policy must be viewed realistically 
with regard to the antidiabetics’ consumption. Adherence to principles of diabetes 
mellitus treatment’s guidelines lead to fundamental short and long term ﬁnancial 
savings within health care systems.
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OBJECTIVES: Exenatide and glargine are used for the treatment of type 2 diabetes 
(T2D) patients who are inadequately controlled on oral antidiabetic (OAD) medica-
tions. This study examined concomitant medications (including “off- label” use), 
resource utilization, and mean HbA1C (A1C) reduction after initiation of exenatide 
compared to glargine. METHODS: A retrospective claims analysis comprised of adult 
patients with T2D who initiated exenatide (N  9264) or glargine (N  3791) therapy 
between April 1, 2005 and June 30, 2007. Concomitant medications and resource 
utilization were estimated using logistic regression with propensity score stratiﬁcation 
used to control for baseline patient characteristics. A subgroup analysis was performed 
in patients who had baseline and follow-up A1C data for exenatide (n  606) and 
glargine (n  251) to examine mean A1C reduction. RESULTS: A higher percentage 
of exenatide-treated patients were using concomitant metformin only (21.4% vs. 
10.7%, p  0.0001) and a lower percentage were using concomitant sulfonylurea only 
(3.2% vs. 6.4%, p  0.001). There was no signiﬁcant differences between percentage 
of patients using at least 1 OAD medication (89.2% vs. 88.9%, p  0.14) in both 
cohorts. Exenatide-treated patients had 26% lower risk of hospitalizations (OR: 0.74, 
p  0.0001) mainly due to 38% lower risk of macrovascular complications (OR: 0.62, 
p  0.001). Exenatide-treated patients also experienced 22% lower risk of hypoglyce-
mic events (OR: 0.78, p  0.037). A higher percentage of exenatide-treated patients 
with a baseline A1C q 7% achieved an A1C goal of  7 (36.3% vs. 19.3%, p  0.001). 
Exenatide-treated patients experienced a signiﬁcantly greater mean reduction in A1C 
compared to glargine-treated patients after adjusting for baseline A1C (0.80 vs. 
0.52, p  0.0142). CONCLUSIONS: Most patients were concomitantly using some 
OAD medications in both cohorts. Exenatide-treated patients had a signiﬁcantly lower 
risk of hospitalizations, macrovascular complications and hypoglycemic events. In the 
patient subset with A1C data, exenatide-treated patients had a signiﬁcantly greater 
reduction in mean A1C and higher percentage achieving goal than glargine-treated 
patients.
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OBJECTIVES: Clinical evidence evaluating polypharmacy and health care utilization 
with the use of continuous subcutaneous insulin infusion (CSII) in persons with 
uncontrolled Type 2 diabetes is limited. This study provides a real-world (retrospec-
tive) evaluation of the impact of CSII among 973 patients with Type 2 diabetes initiat-
ing CSII therapy between January 2005–October 2007 (mean age 48 years, 47% male, 
mean duration of follow-up 17 months). We hypothesized that CSII therapy would 
reduce rates of polypharmacy (multiple diabetes medication use), ER visits, and hos-
pitalizations. METHODS: Administrative claims from a large, geographically diverse, 
US health plan were used. RESULTS: More than 1/3 of subjects taking oral anti-dia-
betic medications (OADs) before CSII initiation discontinued oral therapy altogether 
once they began CSII. The mean number of OADs used by subjects decreased by 0.67 
OADs (1.45 OADs before vs. 0.78 OADs after, p  0.001) after CSII initiation. The 
number of subjects using multiple OADs decreased by 58% (40% before vs. 17% 
after, p  0.001) and rates of switching or augmenting oral therapy decreased from 
44% to 25% (p  0.001) from baseline to follow-up. The rate of ambulatory visits 
increased from pre- to post-CSII initiation (1.80 visits/subject/month before vs. 2.01 
visits/subject/month after CSII initiation, p  0.01), likely reﬂecting increased use of 
diabetes education services related to CSII. However, the rates of ER visits (0.11 
visits/subject/month before vs. 0.08 visits/subject/month after, p  0.01) and hospital-
izations (0.03 visits/subject/month before vs. 0.01 visits/subject/month after, p  0.01) 
signiﬁcantly decreased after CSII initiation. CONCLUSIONS: Insulin pump therapy 
(CSII) was associated with signiﬁcant decreases in polypharmacy and medication 
changes. Also, CSII may lead to a reduction in health care utilization as indicated by 
reductions in rates of ER visits and hospitalizations.
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Diabetes is one of the most prevalent diseases of 21st century. In Greece, according to 
IDF, 737.700 people were suffering from diabetes in 2006 with prevalence rate 8.6% 
of the adult population. The Greek NHS decides reimbursement level based on disease. 
Nevertheless a paradox that exists in Diabetes case is that insulins are fully reimbursed 
whereas oral medications are reimbursed 75%. Moreover, the blood glucose measur-
ing tapes are distributed for free in patients taking insulin, contrary to patients in 
oral medications that have to pay the whole amount. OBJECTIVES: To assess the 
